Heska (HSKA) Misses Q1 EPS by 1c

Heska (NASDAQ: HSKA) reported Q1 EPS of $0.09, $0.01 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $22.9 million versus the consensus estimate of $23.97 million.

Kevin Wilson, Heska's Chief Executive Officer and President, commented that, "Heska continued its strong momentum in the quarter by expanding margins, selling more, and spending less per revenue dollar doing it. Heska had success in key broad initiatives and in the details during the quarter. The feedback from customers of our newly launched Element HT5 five-part hematology analyzer was excellent. Our close relationship with Henry Schein Animal Health is going very well and gaining momentum. During the period, we grew our net customer base in all key segments, including the highly competitive blood analyzer space, where roughly eight in ten new analyzer customers upgraded to Heska from a competitor. We are executing well, our pipeline is at record levels, and we are working hard on new initiatives."

For earnings history and earnings-related data on Heska (HSKA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Optimum Communications gets NYSE non-compliance notice over stock price
• Diana Shipping drops bid for Genco after price demands spike to $36.91